Logotype for Oncoclínicas do Brasil Serviços Médicos S A

Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oncoclínicas do Brasil Serviços Médicos S A

Q2 2026 earnings summary

17 Aug, 2026

Executive summary

  • Faced significant operational and financial headwinds in Q2 2026, including a drug/medication supply crisis, liquidity constraints, and cash flow pressures, but maintained care quality and advanced restructuring and cost optimization initiatives.

  • Implemented a R$150 million private financing agreement to stabilize medicine supply and engaged in creditor negotiations to realign debt amortization and strengthen financial capacity.

  • Non-recurring accounting adjustments, including credit loss provisions, impairments, and contract termination penalties, significantly affected results.

  • Entered judicial recovery in July 2026 to restructure approximately R$5.1 billion in financial debt, with all debt reclassified as short-term due to covenant breaches.

  • Continued focus on sustainable growth, profitability, and transparent communication with the market.

Financial highlights

  • Gross revenue for Q2 2026 was R$1,227.6 million, down 25.9% year-over-year; net revenue was R$1,047.7 million, down 28.5% year-over-year, mainly due to medication shortages and asset sales.

  • Adjusted EBITDA for Q2 2026 was R$34.3 million (margin 9.5% excluding PCLD), but only R$34.2 million (margin 3.3%) including all effects; net loss for the quarter was R$475.7 million, with net loss ex-hospitals at R$425 million.

  • Gross margin, excluding non-recurring effects, was 27.2%; accounting gross margin was 21.9%–22.2%.

  • Cash flow from operations was positive at R$158.4 million, mainly due to renegotiated supplier terms and normalization of receivables.

  • Net debt at quarter-end was R$3.4 billion, with total debt at R$3,686.7 million and cash position at R$129.0–R$160.9 million.

Outlook and guidance

  • Recovery is expected to be gradual, with ongoing discipline in executing the restructuring plan, cost optimization, and asset divestitures to restore profitability and liquidity.

  • Management remains focused on operational turnaround, considering inorganic initiatives and further operational adjustments.

  • Judicial recovery aims to provide a stable environment for debt renegotiation and operational continuity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more